Twist Bioscience Corporation revised earnings guidance for the fiscal year 2024. For the full fiscal year 2024, total revenue is expected to be in the range of $300 million to $304 million compared to previous guidance of $288 million to $293 million, indicating year over year growth of 22% to 24%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
50.46 USD | -4.79% | +20.43% | +36.90% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.90% | 2.94B | |
+0.82% | 91.94B | |
-1.32% | 38.74B | |
-12.88% | 32.82B | |
+64.77% | 26.66B | |
-16.31% | 15.32B | |
-11.38% | 11.65B | |
+173.10% | 10.37B | |
-49.84% | 10.12B | |
+5.24% | 9.06B |
- Stock Market
- Equities
- TWST Stock
- News Twist Bioscience Corporation
- Twist Bioscience Corporation Revises Earnings Guidance for the Fiscal Year 2024